CLINICAL UPDATES Non-Hodgkin lymphoma

被引：92

作者：

Al-Naeeb, Anna Bowzyk ^{[1
]}

Ajithkumar, Thankamma ^{[2
]}

Behan, Sarah ^{[3
]}

Hodson, Daniel James ^{[3
,4
]}

机构：

[1] Bedford Hosp, Dept Oncol, Bedford, England

[2] Cambridge Univ Hosp NHS Trust, Dept Oncol, Cambridge, England

[3] Cambridge Univ Hosp NHS Trust, Dept Haematol, Cambridge, England

[4] Univ Cambridge, Wellcome Trust, Med Res Council, Stem Cell Inst, Cambridge, England

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2018年 / 362卷

关键词：

B-CELL LYMPHOMA; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; MALIGNANCY RESEARCH NETWORK; FOLLICULAR LYMPHOMA; ADVANCED-STAGE; OPEN-LABEL; HEMATOLOGICAL MALIGNANCY; 1ST-LINE TREATMENT; HIGH-RISK;

D O I：

10.1136/bmj.k3204

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页数：7

共 34 条

[21]

Morton Lindsay M., 2014, Journal of the National Cancer Institute Monographs, P130, DOI 10.1093/jncimonographs/lgu013

[22] Epidemiology of non-Hodgkin's lymphoma (NHL):: trends, geographic distribution, and etiology [J].

Müller, AMS ;

Ihorst, G ;

Mertelsmann, R ;

Engelhardt, M .

ANNALS OF HEMATOLOGY, 2005, 84 (01) :1-12

[23]

National Institute for Health and Care Excellence, 2015, SUSP CANC REC REF NI

[24] Cancers attributable to infection in the UK in 2010 [J].

Parkin, D. M. .

BRITISH JOURNAL OF CANCER, 2011, 105 :S49-S56

[25] CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group [J].

Pfreundschuh, Michael ;

Trumper, Lorenz ;

Osterborg, Anders ;

Pettengell, Ruth ;

Trneny, Marek ;

Imrie, Kevin ;

Ma, David ;

Gill, Devinder ;

Walewski, Jan ;

Zinzani, Pier-Luigi ;

Stahel, Rolf ;

Kvaloy, Stein ;

Shpilberg, Ofer ;

Jaeger, Ulrich ;

Hansen, Mads ;

Lehtinen, Tuula ;

Lopez-Guillermo, Armando ;

Corrado, Claudia ;

Scheliga, Adriana ;

Milpied, Noel ;

Mendila, Myriam ;

Rashford, Michelle ;

Kuhnt, Evelyn ;

Loeffler, Markus .

LANCET ONCOLOGY, 2006, 7 (05) :379-391

[26] Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [J].

Rummel, Mathias J. ;

Niederle, Norbert ;

Maschmeyer, Georg ;

Banat, G. Andre ;

von Gruenhagen, Ulrich ;

Losem, Christoph ;

Kofahl-Krause, Dorothea ;

Heil, Gerhard ;

Welslau, Manfred ;

Balser, Christina ;

Kaiser, Ulrich ;

Weidmann, Eckhart ;

Duerk, Heinz ;

Ballo, Harald ;

Stauch, Martina ;

Roller, Fritz ;

Barth, Juergen ;

Hoelzer, Dieter ;

Hinke, Axel ;

Brugger, Wolfram .

LANCET, 2013, 381 (9873) :1203-1210

[27] Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial [J].

Salles, Gilles ;

Seymour, John Francis ;

Offner, Fritz ;

Lopez-Guillermo, Armando ;

Belada, David ;

Xerri, Luc ;

Feugier, Pierre ;

Bouabdallah, Reda ;

Catalano, John Vincent ;

Brice, Pauline ;

Caballero, Dolores ;

Haioun, Corinne ;

Pedersen, Lars Moller ;

Delmer, Alain ;

Simpson, David ;

Leppa, Sirpa ;

Soubeyran, Pierre ;

Hagenbeek, Anton ;

Casasnovas, Olivier ;

Intragumtornchai, Tanin ;

Ferme, Christophe ;

da Silva, Maria Gomes ;

Sebban, Catherine ;

Lister, Andrew ;

Estell, Jane A. ;

Milone, Gustavo ;

Sonet, Anne ;

Mendila, Myriam ;

Coiffier, Bertrand ;

Tilly, Herve .

LANCET, 2011, 377 (9759) :42-51

[28] Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study [J].

Salles, Gilles ;

Mounier, Nicolas ;

de Guibert, Sophie ;

Morschhauser, Franck ;

Doyen, Chantal ;

Rossi, Jean-Francois ;

Haioun, Corinne ;

Brice, Pauline ;

Mahe, Beatrice ;

Bouabdallah, Reda ;

Audhuy, Bruno ;

Ferme, Christophe ;

Dartigeas, Caroline ;

Feugier, Pierre ;

Sebban, Catherine ;

Xerri, Luc ;

Foussard, Charles .

BLOOD, 2008, 112 (13) :4824-4831

[29] The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP [J].

Sehn, Laurie H. ;

Berry, Brian ;

Chhanabhai, Mukesh ;

Fitzgerald, Catherine ;

Gill, Karamjit ;

Hoskins, Paul ;

Klasa, Richard ;

Savage, Kerry J. ;

Shenkier, Tamara ;

Sutherland, Judy ;

Gascoyne, Randy D. ;

Connors, Joseph M. .

BLOOD, 2007, 109 (05) :1857-1861

[30] Pathogenesis of Human B Cell Lymphomas [J].

Shaffer, Arthur L., III ;

Young, Ryan M. ;

Staudt, Louis M. .

ANNUAL REVIEW OF IMMUNOLOGY, VOL 30, 2012, 30 :565-610

← 1 2 3 4 →